GlobeNewswire Inc.··Portnoy Law FirmAardvark Therapeutics Stock Crashes 56% After Trial Pause; Fraud Investigation Launched
Aardvark Therapeutics stock plummeted 56.2% after halting Phase 3 trial due to cardiac observations. Law firm investigates potential securities fraud.
AARDsecurities fraudclass action lawsuit